#Graft Versus Host Disease Market Symptoms

[deshpandeisha]

Understanding Chronic Graft-versus-Host Disease: Causes, Symptoms, and Diagnosis

The global Chronic Graft-versus-Host Disease (cGvHD) market size reached USD 3.5 Billion in 2021 and is expected to register a revenue CAGR of 13.3% during the forecast period, according to the latest analysis by Emergen Research. Increasing number of allogenic transplants such as bone marrow transplants, rising regulatory approvals for the treatment of Graft Versus Host Disease (GvHD) as well as increase in prevalence of nephrological leukemia, myeloma, and other forms of cancer are some of the key factors driving revenue growth of the chronic graft-versus-host disease market.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1640

Competitive Terrain:

The global Chronic Graft versus Host Disease industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Merck KGaA, Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., F. Hoffman-La Roche Ltd, Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, and Takeda Pharmaceutical Company Limited

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Chronic Graft versus Host Disease market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Chronic Graft versus Host Disease market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Chronic Graft versus Host Disease market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1640

Market Segmentations of the Chronic Graft versus Host Disease Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Chronic Graft versus Host Disease market on the basis of product, application, and region:

Segments Covered in this report are:

Treatment Type Outlook (Revenue, USD Billion; 2019-2030)

Corticosteroids

mTOR inhibitors

Tyrosine Kinase Inhibitors (TKIs)

Monoclonal Antibodies

Photopheresis light treatment (ECP)

Others

Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

Regional Outlook (Revenue, USD Billion; 2019-2030)

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

U.A.E.

South Africa

Turkey

Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/chronic-graft-versus-host-disease-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1640

[sanpdr1994]

Graft Versus Host Disease (GvHD) Treatment Market Types Applications Products Share Growth Insights And Forecasts Report 2032

The global Graft Versus Host Disease (GvHD) Treatment Market is expected to secure US$ 5,655.37 Million in 2032 while expanding at a CAGR of 8.3%.

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors.

Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.

It is tough to diagnose who might develop GvHD after a transplant. Mild form of GvHD is observed in few cases. While in certain cases GvHD may be fatal. GvHD do not occur when recipient receives their own cells through autologous transplant. Prior to a transplant, cells from possible donors are screened to realize how strictly they match the recipient. Chances of GvHD are reduced, or symptoms will be milder, when the match is close.

There are two forms of GvHD:

Acute graft versus host disease (aGvHD).

Chronic graft versus host disease (cGvHD).

Graft Versus Host Disease (GvHD) Treatment Market: Drivers and Restraints

Presently, graft versus host disease (GvHD) market is driven by increase in number of incidence and prevalence of cancer patients which are treated by chemotherapy treatment. Graft versus host disease (GvHD) global market is also fueled by increase in number of bone marrow transplants been carried around the globe to treat specific types of cancers.

Increase in allogeneic hematopoietic stem cell transplant will play key role in global market for graft versus host disease (GvHD). However, cost linked with recent clinical trials and authorizations would acts as a major restraint for graft versus host disease (GvHD) global market.

Graft versus Host Disease (GvHD) Treatment Market: Overview

The global market graft versus host disease (GvHD) treatment is expected to register a healthy CAGR during the forecast period. Innovative development of novel technologies, and increase in the number of cancer patients seeking for chemotherapy treatment is expected to drive the growth of graft versus host disease (GvHD) treatment market in the forecast period (2016-2026).

Graft versus Host Disease (GvHD) Treatment Market: Key Players

Some of the key participating global players in graft versus host disease (GvHD) treatment global market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Key Segments Profiled In The Global Graft Versus Host Disease (Gvhd) Treatment Market

Graft Versus Host Disease (GvHD) Treatment Market by Product:

Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment

mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment

Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment

Thalidomide Graft Versus Host Disease (GvHD) Treatment

Etanercept Graft Versus Host Disease (GvHD) Treatment

Graft Versus Host Disease (GvHD) Treatment Market by Disease:

Acute Graft Versus Host Disease (a(GvHD))

Chronic Graft Versus Host Disease (c(GvHD))

Graft Versus Host Disease (GvHD) Treatment Market by Region:

North America Graft Versus Host Disease (GvHD) Treatment Market

Latin America Graft Versus Host Disease (GvHD) Treatment Market

Europe Graft Versus Host Disease (GvHD) Treatment Market

Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market

Middle East & Africa Graft Versus Host Disease (GvHD) Treatment Market

[deepadelve]

Graft Versus Host Disease Market

Graft versus host disease (GvHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when a particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

DelveInsight's "Graft versus host disease (GVHD) Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Graft versus host disease (GVHD), historical and forecasted epidemiology as well as the Graft versus host disease (GVHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of the Graft versus host disease Market report:

The GvHD market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 15.9%.

In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.

GvHD is categorized into two types: aGvHD and cGvHD.

In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021–2030.

Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.

In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight’s analysis, around 3,278 cases of cGvHD treated in first-line in the United States in 2020

The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.

The key players in GvHD market are:

Imbruvica

Temcell HS

Incyte Corporation

Enlivex Therapeutics

Kiadis Pharma

OncoImmune

And Many Others

GvHD has two types Acute GvHD and Chronic GvHD. Acute GvHD is also known as fulminant GVHD, and occurs usually in the initial 2-3 months after transplantation. While Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucous or saliva.

Acute GVHD is staged and graded (grade I-IV) by the number and extent of organ involvement. While Chronic GvHD is staged according to a new clinical scoring system on a four point scale (0-3) with 0 representing no involvement, 1 representing mild involvement (no significant impairment of daily living), 2 representing moderate involvement (significant impairment of daily living) and 3 representing severe impairment (major disability).

“According to Delveinsight, No significant difference was found in incidence of GvHD among male and female”

The launch of the emerging therapies is expected to significantly impact Graft versus host disease (GvHD) treatment scenario in the upcoming years:-

Graft versus host disease therapies covered:

Imbruvica

Temcell HS

Ruxolitinib

Itacitinib

Allocetra

ATIR101

CD24Fc

And Many Others

Table of contents:

Key Insight

Executive Summary of Graft Versus Host Disease (GvHD)

Graft Versus Host Disease (GvHD) Market Overview at a Glance

Disease Background and Overview: Graft Versus Host Disease (GvHD)

Case Reports

Graft Versus Host Disease (GvHD) Epidemiology and Patient Population

United States Epidemiology

EU5 Epidemiology

Japan Epidemiology

Current Graft Versus Host Disease (GvHD) Treatment and Medical Practices

Unmet needs

Graft Versus Host Disease (GvHD) Marketed Drugs

Graft Versus Host Disease (GvHD) Emerging Drugs

Graft Versus Host Disease (GvHD) 7MM Market Analysis

United States

EU-5 countries: Market Outlook

Japan Market Outlook

Graft Versus Host Disease (GvHD) Market Drivers

Graft Versus Host Disease (GvHD) Market Barriers

SWOT Analysis

Reimbursement and market access

Appendix

DelveInsight Capabilities

Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

[myabhijitr]

Graft Versus Host Disease (GvHD) Market – High investment in research and development is expected to favor growth of the market

Overview:

Graft versus host disease (GvHD) is a condition that might occur after an allogeneic transplant. A condition that occurs when donor bone marrow or stem cells attack the recipient. Gvhd occur especially in immune-compromised patients. Radioactive agents or chemicals affect both the cancer cells and healthy cells during cancer treatment. The reconstruction of affected body cells can be done using stem cells and bone marrow transplant. The bone marrow is obtained from the donor through an infusion after a high dose of chemotherapy, which in turn help to resume the production of blood cells. GvHD occurs when certain white blood cells are not compatible with the existing cell type and, thus, the recipient’s body is attacked by the transplanted cells. The signs and symptoms of graft versus host disease are usually not too severe, although in some cases it can be fatal. Thus, cells of both the recipient and donor are closely screened and matched prior to the transplant to avoid the risk of Gvhd.

Ask for free Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/184

Drivers:

Increasing research and development (R&D) activities is expected to boost the growth of the global graft versus host disease (GvHD) market over the forecast period. The graft versus host disease (GvHD) market has evolved significantly in recent times with the introduction of small molecule immunosuppressant therapies (biological and patented). Moreover, the current R&D programs/activities are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. These programs/activities are characterized by an increasing trend towards maintaining an appropriate prophylactic regimen and inhibiting activation and proliferation of T-cell. Such regimens are used for hematopoietic stem cell transplantation and are tailored to the conditioning and transplant types. However, there is a great potential for risk of opportunistic infection during this process.

However, most R&D strategies/activities, including clinical studies regarding targeting niche subgroup under GvHD, such as steroid refractory cGVHD and aGVHD, are the major R&D strategies in the GVHD pipeline. Extensive R&D activities are expected to drive growth of the global graft versus host disease market during the forecast period.

Moreover, rise in need for GvHD management is also expected to aid in the global graft versus host disease market growth. There are currently few or no guidelines for GvHD management that can accurately maintain data from large populations suffering from GvHD, although some recommendations exist for such treatments.

Furthermore, graft versus host disease is orphan in nature, which may be one of the important factors influencing the treatment regimes and lack of guidelines. Lack of randomized clinical trials and non-popularity of Gvhd is another factor that is expected to hamper the growth of the market. This in turn has resulted in inappropriate clinical evidence, which are not comparable and not applicable to all GvHD patients. However, advancements in early detection process is expected to propel the global graft versus host disease market growth.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐎 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏

Buy This Complete Business Report @  https://www.coherentmarketinsights.com/insight/buy-now/184

Market players are engaged in R&D to enhance the outcomes of the therapy, which in turn is also expected to aid in the growth of the market. For instance, in 2017, an international research team led by the University of Michigan Life Sciences Institute revised the understanding of the key cellular and molecular events that trigger GvHD.

Moreover, market players are focusing on launching novel products, as well as are adopting various strategies, such as merger and acquisition, to gain competitive edge in the market and to strengthen their product portfolio. For instance, in February 2017, Kalytera Therapeutics, Inc. announced that it has completed the previously announced acquisition of Talent Biotechs Ltd. to strengthen its position as an emerging market leader in cannabidiol pharmaceuticals.

Competitive Landscape:

Key players operating in the global graft versus host disease market are Novartis AG, Sanofi, Merck & Co., Astellas Pharma, Mesoblast Ltd., Soligenix, Inc., and Neovii Biotech GmbH, among others.

Key Developments:

In May 2019, the Food and Drug Administration (FDA) approved ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory GvHD in adult and pediatric patients 12 years and older.

In November 2017, Merck & Co., Inc., received FDA approval for PREVYMIS (letermovir), once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for the patients suffering from GvHD.

In August 2017, Pharmacyclics LLC received FDA approval for Imbruvica (ibrutinib) drug, for the treatment of adult patients with chronic GvHD.

[mrunalnerkarblog]

Graft Versus Host Disease (GvHD) Market :How the Market will perform in Upcoming Years based on Market Size, Share, Supply Volume and Major Regions

During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a high dose of chemotherapy, the bone marrow is received by patient the donor through infusion, which helps with resumption of blood cells production. Graft versus host disease occurs when particular type of white blood cells are not compatible with the existing cell type and thus, leads to an attack by the transplanted cells on the recipient body. It is a difficult procedure to diagnose the agents and the compatibility during the transplant. Symptoms of Gvhd are usually not too severe, though in some cases it can be fatal. During autologous transplant, the patient is free from such complications. Also, prior to the transplant, cells of the donor and recipient are closely screened and matched so as to avoid Gvhd by ensuring the closest possible match.

Request for Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/184

Graft Versus Host Disease Market Taxonomy:

By Disease Type

Acute graft vs. host disease (aGvHD)

Chronic graft vs. host disease (cGvHD)

By Product Type

Monoclonal antibodies

mTOR inhibitors

Tyrosine kinase inhibitors

Thalidomide

Etanercept

High investment in research and development is expected to favor growth of the graft versus host disease market:

In the recent past, the graft versus host disease market has significantly evolved with the introduction of biological and patented small molecule immunosuppressive therapies and been added to the treatment regime. The current research and development programs in Gvhd are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. R&D strategies in Gvhd are characterized by an increasing trend towards maintaining appropriate prophylactic regimens and inhibiting proliferation and activation of T-cell. Such regimens in Gvhd are tailored to conditioning and transplant type and used for hematopoietic stem cell transplantation (HSCT). However, there is significant possibility of risk of opportunistic infection during this process.

However, most of the ventures in research and development process, including academically running clinical studies regarding targeting niche subgroup under Gvhd such as steroid refractory aGVHD and cGVHD, are key R&D strategies in the GVHD pipeline, with around 30 products in the pipeline targeting such populations. Extensive research and development activities are expected to favor growth of the graft versus host disease industry in the near future.

Large unmet needs in the Gvhd management are one of the most important factors fueling growth of the graft versus host disease market. At present there are very few or no guidelines for management of graft versus host disease that can precisely maintain the data for the large population suffering from Gvhd, though certain recommendations for such therapies are in place.

Lack of regulatory guidelines pegs back growth of graft versus host disease market

The disease is orphan in nature, which can be one of the important factors affecting the lack of guidelines and treatment regimes. Lack of randomized clinical trials is another factor that contributes towards non-popularity of Gvhd due to the use of variable clinical trial endpoints conducted studies till date. This has resulted in inappropriate clinical evidences, which are not comparable and not directly applicable to all Gvhd patient groups. However, advancements in the process of early detection of symptoms is projected to support growth of the graft versus host disease market in the near future.

Major research universities in the GvHD market are engaged in research and development processes to further enhance the outcomes of the therapy. For instance, research conducted by the University Of Michigan, in 2017, revised the understanding regarding the graft vs. host disease origins, which can offer new direction for potential therapy in the near future.

Market players in the GvHD market focusing on inorganic growth strategies to strength product portfolio

The global graft versus host disease market is competitive and fragmented. Major players in the market are developing novel products and spending significantly in research and development, along with major acquisitions and collaborations to achieve competitive edge over their counterparts. For instance, Kalytera Therapeutics, Inc. acquired Talent Biotechs Ltd. – an Israeli-based developer of proprietary cannabidiol therapeutic. This is expected to favor the increase in company’s product portfolio. Some of the key players in the Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd.

To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/184

Key Developments

Major companies are focused on various growth strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio. For instance, in May 2019, Incyte Corporation, a U.S.-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for ‘Jakafi’, a drug indicated for the treatment of steroid-refractory acute GVHD for adults and pediatric patients aged 12 years and above.

Key players in the market are focused in various business strategies such as gaining product approval from regulatory authorities, in order to gain competitive edge in the market. For instance, in November 2017, Merck & Co., Inc., a pharmaceutical company, received the U.S. FDA approval for PREVYMIS, which is a tablet for oral use and injection for infusion. PREVYMIS is indicated for the patients suffering from GVHD.

Key players in the market are focused in various business strategies such as gaining product approval from regulatory authorities, in order to gain competitive edge in the market. For instance, in August 2017, Pharmacyclics LLC, a biopharmaceutical company, received the U.S. FDA approval for Imbruvica (ibrutinib) drug, which will be used for adult patients with chronic graft versus host disease.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

[kritikarehani]

Immune Thrombocytopenia (ITP) Market Scenario, 2030

DelveInsight’s ‘Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2030

View report: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market

Immune Thrombocytopenia (ITP) Disease Understanding

Immune Thrombocytopenia (ITP) Overview

Immune Thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of ITP stem from a low platelet count leading to excessive bleeding. In severe cases, frequent bleeding episodes may result in low levels of circulating red blood cells (anemia), which may cause fatigue and impair response to exertion. In rare cases, serious bleeding into the brain (intracranial hemorrhage) may occur.

The two main types of ITP are acute (short term) and chronic (long term). ITP is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).

Immune Thrombocytopenia (ITP) Epidemiology  

The Immune Thrombocytopenia epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP scenario of ITP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

·��        Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.

·         DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.

·         The total diagnosed prevalent cases in the 7MM was estimated to be approximately 147,174 in 2017.

Immune Thrombocytopenia (ITP) Epidemiology

The epidemiology segment also provides the ITP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Download our free report: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market

Immune Thrombocytopenia (ITP) Drug Chapters

The drug chapter segment of the ITP report encloses the detailed analysis of Immune Throbocytopenia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the ITP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Immune Thrombocytopenia (ITP) Marketed Drugs

Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals

Fostamatinib disodium (also known as Tavalisse; R-985788) is an orally-bioavailable investigational agent being developed by Rigel pharmaceuticals and approved for the treatment of patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. The therapeutic candidate inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis.

As stated by Rigel Pharmaceuticals, fostamatinib has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase. The company is focusing on the fostamatinib ITP program specifically on the chronic form of this disease targeting the underlying autoimmune cause of the disease rather than stimulating platelet production. Moreover, fostamatinib is also being evaluated for autoimmune hemolytic anemia, IgA nephropathy, graft-versus-host disease, and ovarian cancer.

In June 2017, the company filed for the New Drug Application to the USFDA for the use of fostamatinib in chronic ITP patients. Later in October 2017, Rigel Pharmaceuticals indicated that the FDA anticipated the Prescription Drug User Fee Act (PDUFA) action date for the application review in April 2018. And in April 2018, Tavalisse got approved for the treatment of Idiopathic Thrombocytopenic Purpura.

Products detail in the report…

List to be continued in the report…

Immune Thrombocytopenia (ITP) Emerging Drugs

BT-595: Biotest

BT-595 (IgG Next Generation) is an intravenously administered, novel polyvalent immunoglobulins (IVIG) designed specifically to treat primary immune deficiencies, secondary antibody deficiency syndromes, and several autoimmune disorders. Currently, the company is developing this therapeutic molecule in the Phase III stage of development for the treatment of patients with Immune Thrombocytopenic Purpura (ITP).

Products detail in the report…

Immune Thrombocytopenia (ITP) Market Outlook

The US Food and Drug Administration (FDA) has approved three Thrombopoietin receptor agonist (TPO-RA) therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). For Europe and Japan, only two TPO-RAs is approved, i.e., Nplate and Promacta. Promacta and Nplate will lose their patent in 2022 in the US, whereas, in Europe and Japan, Nplate loses the patent in 2019 and Promacta will lose patent in 2025. Due to their patent expiry, it is expected that the approval of Doptelet is likely to cover a major patient pool.

At present, there have been few well-designed randomized trials targeted at reducing chronic ITP in adults and children. Further prospective trials may be able to enhance the approach and improve overall outcomes. Adequate long-term follow-up will be necessary to determine whether relapse is truly averted or simply delayed. It will also be important to select novel composite outcomes that account for clinical events as well as evaluate the cost and the added adverse events of combined therapies.

In addition to clinical trials, essential research should focus on identifying patients who would benefit from more intensive therapy: for example, the ability to determine those patients who will develop persistent or chronic ITP or identification of markers predictive of who would benefit most from a specific therapy.

According to DelveInsight, ITP 7MM is expected to change in the study period 2017–2030.

Key Findings

·         The Immune Thrombocytopenia market size in the 7MM was found to be USD 2,527.72 million in 2017.

·         The United States accounts for the highest market size of Immune Thrombocytopenia (ITP), in comparison to the other major markets i.e., EU5 countries, and Japan

Request for sample pages of the report, Immune Thrombocytopenia (ITP) Market Outlook: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market

Download our full report@ https://www.delveinsight.com/report-store/immune-thrombocytopenia-market

[speedypeacething-blog]

Chronic Ocular Graft-versus-host Disease Market  -Size,Share And Growth 2019- 2027

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

For requesting free sample latest study on Global Chronic Ocular Graft-versus-host Disease Market, Visit: https://www.meridianmarketconsultants.com/requst?rid=3892

As per the report, rapidly growing prevalence of graft versus host disease and increasing number of stem cell transplantation procedures are identified as major factors driving the growth of chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptom. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjuncitvitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis. Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases chances of development of chronic ocular graft versus host disease.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Chronic Ocular Graft-versus-host Disease Market, Visit:https://www.meridianmarketconsultants.com/global-chronic-ocular-graft-%20versus-host-disease-market

Furthermore, Meridian Market Consultants (MMC) Study identifies that, in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation and cord blood transplantation is a routine procedure and it offers potential cure for life threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders etc. Ocular graft-versus-host disease is one of the major complications of allogenic stem cell transplant. The first line treatment for chronic ocular graft-versus-host disease include immunosuppressant and topical steroids. Immunosuppressant treatment for the chronic ocular graft-versus-host disease are methotrexate, cyclosporine and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation, and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being develop such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in next few years. Amniotic membrane is rich in cytokines, growth factors and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases recurrence of primary condition.

MMC Study identifies some of the key players operating in chronic ocular graft-versus-host disease market market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc. etc.

Read Deatils News: https://meridianmarketconsultants.com/pressrelese/global-chronic-ocular-graft-versus-host-disease-market

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

[mathewwon802]

Chronic Ocular Graft- Versus-Host Disease Market 2019|| Research Report, Growth Forecast 2027

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

For requesting free sample to our latest study on Global Chronic Ocular Graft-versus-host Disease Market, visit: https://www.meridianmarketconsultants.com/requst?rid=3892

As per the report, rapidly growing prevalence of graft versus host disease and increasing number of stem cell transplantation procedures are identified as major factors driving the growth of chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptom. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjuncitvitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis. Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases chances of development of chronic ocular graft versus host disease.

Furthermore, Meridian Market Consultants (MMC) Study identifies that, in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation and cord blood transplantation is a routine procedure and it offers potential cure for life threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders etc. Ocular graft-versus-host disease is one of the major complications of allogenic stem cell transplant. The first line treatment for chronic ocular graft-versus-host disease include immunosuppressant and topical steroids. Immunosuppressant treatment for the chronic ocular graft-versus-host disease are methotrexate, cyclosporine and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation, and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being develop such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in next few years. Amniotic membrane is rich in cytokines, growth factors and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases recurrence of primary condition.

To know the latest insights, qualitative data, trends, quantitative data, and more related toGlobal Chronic Ocular Graft-versus-host Disease Market, visit: https://www.meridianmarketconsultants.com/global-chronic-ocular-graft-%20versus-host-disease-market

MMC Study identifies some of the key players operating in chronic ocular graft-versus-host disease market market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc. etc.

Read Detailed News @: https://meridianmarketconsultants.com/pressrelese/global-chronic-ocular-graft-versus-host-disease-market

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

[pharmaphorumuk]

bluebird bio gets CHMP nod for gene therapy Zynteglo

A European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy for thalassemia, a rare blood disorder.

The Committee for Medicinal Products for Human Use (CHMP) confirmed on Friday that it had issued a positive opinion for the therapy – previously known as LentiGlobin – as a treatment for patients aged 12 years and older with transfusion-dependent beta-thalassemia (TDT) who do not have a specific β0/β0 genotype.

The announcement came after a couple of medical charities jumped the gun and prematurely issued notices of the panel’s endorsement last week, hailing it as a major advance for patients with TDT who typically need frequent blood transfusions to manage the disease.

The positive opinion for Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) puts bluebird bio on course for its first gene therapy approval in the coming weeks and could give thalassaemia patients a new one-shot treatment option that tackles the underlying genetic cause of the disease.

A recent analysis by Clarivate suggested the gene therapy was one of the top launches to watch this year, with sales predicted to reach $1.12 billion by 2023 assuming it also gets approved in sickle cell disease. Zynteglo hasn’t been filed for approval yet in the US, but is tipped for a verdict from the FDA in 2021.

TDT is a severe genetic disease characterised by reduced or absent haemoglobin levels that results in ineffective red blood cell production and severe anaemia.

Supportive care consists of a lifelong regimen of chronic blood transfusions to improve survival and suppress symptoms of the disease – but those transfusions can also lead to complications including iron overload that has to be managed with iron chelation therapy.

A cure can be attempted using allogeneic hematopoietic stem cell transplantation (HSCT), but this carries significant risks including treatment-related mortality, graft failure, graft versus host disease (GvHD) and opportunistic infections. Zynteglo is approved for patients with no matching donor for a stem cell transplant.

Zynteglo was reviewed under the EMA’s PRIority MEdicines (PRIME) scheme for promising new medicines and went from filing to positive opinion in just 150 days, which the CHMP says is the shortest timeframe for any advanced therapy medicinal product (ATMP) to date.

Data published last year from two pivotal trials – Northstar and HGB-205 – showed that 12 out of 13 non-β0/β0 patients had become independent of regular transfusions, with a median time since the last transfusion of 27 months, with a range of between 11 months and 42 months.

“The goal of treatment with Zynteglo is to enable patients with transfusion-dependent β-thalassemia to produce haemoglobin at sufficient levels to allow lifelong independence from blood transfusions,” said David Davidson, bluebird bio’s chief medical officer.

“The positive CHMP opinion for Zynteglo is a crucial step toward providing what would be the first one-time gene therapy for people living with TDT.”

Bluebird Bio has been ramping up its operations in anticipation of an approval, and has a commercial-scale manufacturing contract with contract manufacturer Novasep that will help it supply the EU market, along with agreements with clinics that will deliver the therapy. It is also setting up its own manufacturing facility in the US that is expected to come on-line around the time that the gene therapy is approved by the FDA.

Mindful of the ongoing controversy over pricing of new medicines, the biotech has also been talking about a new payment model that might include an upfront fee and payment on instalment that are contingent on the therapy still working as expected. The maximum price of the therapy would be $2.1 million, according to the proposals.

The post bluebird bio gets CHMP nod for gene therapy Zynteglo appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/bluebird-bio-gets-chmp-nod-for-gene-therapy-zynteglo/

[brajeshupadhyay]

Unregulated use of plasma therapy for COVID-19 can be harmful, writes expert; can expose patients to serious transfusion-related risks

Since the beginning of the COVID-19 crisis, the global scientific community is struggling to find solutions to stop the spread of the contagion and to effectively treat the infection caused by it. As this is a new and evolving crisis and it has taken the world by storm, abundant theories and remedies are floating around, but no definitely proven therapy has emerged.

While the disease spread is currently being countered with WHO advocated strategies of containment with lockdown, patient identification by testing for infection and quarantine of patients and suspected patients, these strategies will only slow down the spread of the disease but the world will still need treatment and a vaccine for the prevention of infection.

Some vaccines are under development and will need months before they hit the market, if at all. In the meantime, the global spread of the infection is killing thousands of people daily and there is a severe need to treat the patients with specific medications and other therapy directed at the virus in addition to standard care.

There are a few contender medicines including the malaria drug hydroxychloroquine, an antiviral Remdesivir, and Ivermectin, a drug used for worms and other parasites, but the results are not hugely encouraging and at times conflicting. In this backdrop, plasma therapy is being seen with interest as a cure for COVID-19 patients.

What is plasma?

Human blood is composed of cells like the red cells that carry oxygen, white cells that fight infection and platelets that stop bleeding from cuts. The watery part contains minerals and many proteins like albumin, factors that make the blood clot, and antibodies which are special proteins produced by the body against infective agents. The serum is the plasma from which the clotting factors have been removed.

What is plasma therapy?

Plasma transfusion is a very common process done during major surgeries and in patients with bleeding, mainly to provide clotting factors.

The main component of interest in plasma therapy and serum therapy for infectious diseases like COVID-19 is the antibodies. The principle applied is that a person who has recovered from the infection would have antibodies directed against the infective agent, in this case, the COVID-19 virus.

Click here for Coronavirus Outbreak LIVE Updates

It is assumed that if injected to a person currently having the disease the antibodies would neutralise the virus, helping in achieving an early cure. Injecting the plasma or serum from patients who have recovered from the disease, called convalescent plasma, may achieve this.

Plasma therapy has been used earlier with some success in other infections like in two previous corona viral epidemics SARS-CoV1 and MERS, and also in H1N1 of 2009-10 and Ebola epidemic. Likewise, the animal serum is widely used in the treatment of diseases like tetanus, diphtheria, gas gangrene, botulism, snake and spider bite.

How is plasma therapy done for COVID-19?

Convalescent plasma transfusion is a relatively easy process. It involves collecting plasma by a process called apheresis or whole blood collection as for blood transfusion followed by separation of the plasma in the laboratory from patients who have recovered from the infection.

The donor is tested as for any blood donor and the plasma is then subjected to standard testing as for blood transfusion. In addition, a few more criteria are to be fulfilled which include a positive diagnostic or serological test in the donor and sufficient time has passed since recovery to render the plasma non-infective.

If the donor is female then a special class of antibody called HLA antibody should be absent in the plasma. The donated plasma must have sufficient antibodies against COVID-19 to offer treatment value.

Which COVID-19 patients can have plasma therapy

Currently, India has not framed any guideline for mass use of plasma therapy in COVID-19 patients. The Indian Council of Medical Research (ICMR), the apex medical body in India, is still conducting a trial on the effectiveness of the therapy.

A few centres in India have used it but the number of patients treated is few. The USFDA, the apex body in the US regulating food and drugs and medical equipment and therapies, has on its 13 April 2020 recommendations suggested that plasma therapy be used:

In registered clinical trials for investigational use

expanded access for use in seriously ill patients who are not eligible or are unable to participate in a clinical trial

single patient use of an investigational drug in case of a life-threatening situation on the advice of a licensed physician under FDA authorisation. This is like using the medicine on compassionate ground. Random use of the therapy for COVID-19 patients in the absence of patient selection and treatment guidelines formulated by scientific bodies has not been approved in any country. Significantly, the Union health ministry advised against considering plasma therapy as regular therapy for COVID-19 patients and added that it should only be used for research and trials at present.

Why caution is being exercised on using plasma therapy

At present plasma therapy for COVID-19 is still under investigation and concrete data on its usefulness is not available. All medical devices and drugs pass through stringent evaluation for safety before allowed to be used as a regular therapy.

Plasma transfusion carries a number of risks, some of which are very serious. These include transfusion-related acute lung injury (TRALI) which can cause breathing difficulty/respiratory failure, transfusion-associated circulatory overload (TACO) which can cause heart failure symptoms, allergic reactions or life-threatening anaphylactic shock, risk of infection from other pathogens in the donor's plasma or acquired during processing, fever, graft vs host disease, hemolysis or breakdown of red blood cells in the recipient etc.

Also, we still don’t know exactly at what stage of the illness the patient should be treated, what should exclude a patient from getting this treatment, how much antibody should be present in the plasma to provide the benefit of treatment.

Since every medical therapy has to be decided on risk versus benefit ratio, till the time a clear benefit from the therapy against the disease is established and the benefit clearly outscore the risk it can be harmful to the community if allowed for use beyond controlled settings.

What the available evidence is for its use

Previous studies, though with some flaws in study design, on the use of plasma therapy on H1N1 (Spanish flu), swine flu, SARS-CoV1 has documented positive results. A 2014 Meta-analysis of studies on the use of plasma therapy in influenza and corona viral infections showed a consistent reduction in mortality.

Incidence of severe adverse effects has been quite low. This evidence forms the basis of trying plasma therapy in the current pandemic. However, the pool of evidence on the use of plasma on the COVID-19 is quite small, given the time frame of the disease. We will still need to wait for results from investigational trials to know the answer.

Is there a chance for plasma in COVID-19?

Like many of the options already explored for COVID-19, this is one of the options. It may show modest success, good success or no success. Plasma therapy has always been used in the past and in a variety of conditions but almost always the advent of a vaccine or an antibiotic has pushed plasma therapy to the background.

If it proves to be of some success it will be approved for use in regular clinical settings by regulatory and scientific bodies. If approved for use it will definitely buy some time and save a few lives till a vaccine is available or herd immunity is developed.

It is a promising solution at the present gloomy situation, but till we have reliable evidence on utility unregulated use is to be avoided, as random use does not contribute meaningfully to the database from which a useful conclusion can be drawn. A lot of studies are going on the world over on its use, and hopefully, we will soon know the answer.

The author is a consultant anesthesiologist in a private hospital in Delhi-NCR.

via Blogger https://ift.tt/2KKLB8E

[kevinwmmc1]

Chronic Ocular Graft- Versus-Host Disease Market Size, Share, Trends, Forecast Report 2019 to 2027

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

For requesting free sample related to our latest study on Global Chronic Ocular Graft-versus-host Disease Market, visit: https://www.meridianmarketconsultants.com/requst?rid=3892

As per the report, rapidly growing prevalence of graft versus host disease and increasing number of stem cell transplantation procedures are identified as major factors driving the growth of chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptom. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjuncitvitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis. Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases chances of development of chronic ocular graft versus host disease.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Chronic Ocular Graft-versus-host Disease Market, visit:

https://www.meridianmarketconsultants.com/global-chronic-ocular-graft-%20versus-host-disease-market

Furthermore, Meridian Market Consultants (MMC) Study identifies that, in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation and cord blood transplantation is a routine procedure and it offers potential cure for life threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders etc. Ocular graft-versus-host disease is one of the major complications of allogenic stem cell transplant. The first line treatment for chronic ocular graft-versus-host disease include immunosuppressant and topical steroids. Immunosuppressant treatment for the chronic ocular graft-versus-host disease are methotrexate, cyclosporine and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation, and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being develop such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in next few years. Amniotic membrane is rich in cytokines, growth factors and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases recurrence of primary condition.

MMC Study identifies some of the key players operating in chronic ocular graft-versus-host disease market market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc. etc.

Chronic Ocular Graft- Versus-Host Disease Market, For more visit:

https://meridianmarketconsultants.com/pressrelese/global-chronic-ocular-graft-versus-host-disease-market

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

[blogjamesw123]

Chronic Ocular Graft- Versus-Host Disease Market  Research Report with Latest Trends and Analysis 2019-2027

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

For requesting free sample and PDF Brochure related to our latest study on Global Chronic Ocular Graft-versus-host Disease Market, visit: https://www.meridianmarketconsultants.com/requst?rid=3892

As per the report, rapidly growing prevalence of graft versus host disease and increasing number of stem cell transplantation procedures are identified as major factors driving the growth of chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptom. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjuncitvitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis. Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases chances of development of chronic ocular graft versus host disease.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Chronic Ocular Graft-versus-host Disease Market, click the link below: https://www.meridianmarketconsultants.com/global-chronic-ocular-graft-%20versus-host-disease-market

Furthermore, Meridian Market Consultants (MMC) Study identifies that, in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation and cord blood transplantation is a routine procedure and it offers potential cure for life threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders etc. Ocular graft-versus-host disease is one of the major complications of allogenic stem cell transplant. The first line treatment for chronic ocular graft-versus-host disease include immunosuppressant and topical steroids. Immunosuppressant treatment for the chronic ocular graft-versus-host disease are methotrexate, cyclosporine and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation, and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being develop such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in next few years. Amniotic membrane is rich in cytokines, growth factors and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases recurrence of primary condition.

Read detailed News@:https://meridianmarketconsultants.com/pressrelese/global-barrette-esophagus-market

MMC Study identifies some of the key players operating in chronic ocular graft-versus-host disease market market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc. etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

[wtwilliam79world]

Chronic Ocular Graft- Versus-Host Disease Market Overview, Demand And Growth Analysis Report 2019-2027

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Chronic Ocular Graft-versus-host Disease Market,visit : https://www.meridianmarketconsultants.com/global-chronic-ocular-graft-%20versus-host-disease-market

As per the report, rapidly growing prevalence of graft versus host disease and increasing number of stem cell transplantation procedures are identified as major factors driving the growth of chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptom. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjuncitvitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis. Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases chances of development of chronic ocular graft versus host disease.

For requesting free sample and PDF Brochure related to our latest study on Global Chronic Ocular Graft-versus-host Disease Market, click the link below : https://www.meridianmarketconsultants.com/requst?rid=3892

Furthermore, Meridian Market Consultants (MMC) Study identifies that, in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation and cord blood transplantation is a routine procedure and it offers potential cure for life threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders etc. Ocular graft-versus-host disease is one of the major complications of allogenic stem cell transplant. The first line treatment for chronic ocular graft-versus-host disease include immunosuppressant and topical steroids. Immunosuppressant treatment for the chronic ocular graft-versus-host disease are methotrexate, cyclosporine and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation, and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being develop such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in next few years. Amniotic membrane is rich in cytokines, growth factors and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases recurrence of primary condition.

MMC Study identifies some of the key players operating in chronic ocular graft-versus-host disease market market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc. etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

[meridianmarketconsultants-blog]

Increased Penetration of Stem Cell Therapy is expected to Push the Market for Chronic Ocular graft-versus-host Disease

Meridian Market Consultants (MMC) has published a new report titled, “Chronic Ocular Graft-versus-host Disease Market: Opportunity Analysis and Future Assessment 2019 to 2027”

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa)is expected to grow at a significant CAGR for the period between 2019 and 2027.

To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Chronic Ocular Graft-versus-host Disease Market, click the link below:

https://www.meridianmarketconsultants.com/global-chronic-ocular-graft-%20versus-host-disease-market

As per the report, rapidly growing prevalence of graft versus host disease and increasing number of stem cell transplantation procedures are identified as major factors driving the growth of chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptom. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjuncitvitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis. Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases chances of development of chronic ocular graft versus host disease.

For requesting free sample and PDF Brochure related to our latest study on Global Chronic Ocular Graft-versus-host Disease Market, click the link below:

For Sample: https://www.meridianmarketconsultants.com/requst?rid=3892

For PDF Brochure: https://www.meridianmarketconsultants.com/pdf?rid=3892

Furthermore, Meridian Market Consultants (MMC) Study identifies that in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation and cord blood transplantation is a routine procedure and it offers a potential cure for life-threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders, etc. Ocular graft-versus-host disease is one of the major complications of allogeneic stem cell transplant. The first-line treatment for chronic ocular graft-versus-host disease includes immunosuppressants and topical steroids. Immunosuppressant treatment for the chronic ocular graft-versus-host disease is methotrexate, cyclosporine, and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being developed such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in the next few years. Amniotic membrane is rich in cytokines, growth factors, and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases the recurrence of the primary condition.

MMC Study identifies some of the key players operating in chronic ocular graft-versus-host disease market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc., etc.

About Meridian Market Consultants (MMC):

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

13121, Louetta Road,

#440, Cypress, Texas 77429

United States

Tel: +1-(281)-619-8646

For Sales Queries: sales@meridianmarketconsultants.com

For New Topics and Other Info: info@meridianmarketconsultants.com

[expertofmarketinsights-blog]

Graft Versus Host Disease (GvHD) Market Necessity And Demand 2018 to 2026

During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a high dose of chemotherapy, the bone marrow is received by patient the donor through infusion, which helps with resumption of blood cells production. Click To Read More On Graft Versus Host Disease (GvHD) Market.

Graft versus host disease occurs when particular type of white blood cells are not compatible with the existing cell type and thus, leads to an attack by the transplanted cells on the recipient body. It is a difficult procedure to diagnose the agents and the compatibility during the transplant. Symptoms of Gvhd are usually not too severe, though in some cases it can be fatal. During autologous transplant, the patient is free from such complications. Also, prior to the transplant, cells of the donor and recipient are closely screened and matched so as to avoid Gvhd by ensuring the closest possible match.

High investment in research and development is expected to favor growth of the graft versus host disease market:

In the recent past, the graft versus host disease market has significantly evolved with the introduction of biological and patented small molecule immunosuppressive therapies and been added to the treatment regime. The current research and development programs in Gvhd are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. R&D strategies in Gvhd are characterized by an increasing trend towards maintaining appropriate prophylactic regimens and inhibiting proliferation and activation of T-cell. Such regimens in Gvhd are tailored to conditioning and transplant type and used for hematopoietic stem cell transplantation (HSCT). However, there is significant possibility of risk of opportunistic infection during this process.

However, most of the ventures in research and development process, including academically running clinical studies regarding targeting niche subgroup under Gvhd such as steroid refractory aGVHD and cGVHD, are key R&D strategies in the GVHD pipeline, with around 30 products in the pipeline targeting such populations. Extensive research and development activities are expected to favor growth of the graft versus host disease industry in the near future.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/184

Market players in the GvHD market focusing on inorganic growth strategies to strength product portfolio

The global graft versus host disease market is competitive and fragmented. Major players in the market are developing novel products and spending significantly in research and development, along with major acquisitions and collaborations to achieve competitive edge over their counterparts. For instance, Kalytera Therapeutics, Inc. acquired Talent Biotechs Ltd. – an Israeli-based developer of proprietary cannabidiol therapeutic. This is expected to favor the increase in company’s product portfolio. Some of the key players in the Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd.

Lack of regulatory guidelines pegs back growth of graft versus host disease market

The disease is orphan in nature, which can be one of the important factors affecting the lack of guidelines and treatment regimes. Lack of randomized clinical trials is another factor that contributes towards non-popularity of Gvhd due to the use of variable clinical trial endpoints conducted studies till date. This has resulted in inappropriate clinical evidences, which are not comparable and not directly applicable to all Gvhd patient groups. However, advancements in the process of early detection of symptoms is projected to support growth of the graft versus host disease market in the near future.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[healthcaretrends-blog]

Graft Versus Host Disease Market by Companies, Region, Type and End-use Industry 2019 – 2026

During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a high dose of chemotherapy, the bone marrow is received by patient the donor through infusion, which helps with resumption of blood cells production. Graft versus host disease occurs when particular type of white blood cells are not compatible with the existing cell type and thus, leads to an attack by the transplanted cells on the recipient body. It is a difficult procedure to diagnose the agents and the compatibility during the transplant. Symptoms of Gvhd are usually not too severe, though in some cases it can be fatal. During autologous transplant, the patient is free from such complications. Also, prior to the transplant, cells of the donor and recipient are closely screened and matched so as to avoid Gvhd by ensuring the closest possible match.

High investment in research and development is expected to favor growth of the graft versus host disease market:

In the recent past, the graft versus host disease market has significantly evolved with the introduction of biological and patented small molecule immunosuppressive therapies and been added to the treatment regime. The current research and development programs in Gvhd are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. R&D strategies in Gvhd are characterized by an increasing trend towards maintaining appropriate prophylactic regimens and inhibiting proliferation and activation of T-cell. Such regimens in Gvhd are tailored to conditioning and transplant type and used for hematopoietic stem cell transplantation (HSCT). However, there is significant possibility of risk of opportunistic infection during this process.

However, most of the ventures in research and development process, including academically running clinical studies regarding targeting niche subgroup under Gvhd such as steroid refractory aGVHD and cGVHD, are key R&D strategies in the GVHD pipeline, with around 30 products in the pipeline targeting such populations. Extensive research and development activities are expected to favor growth of the graft versus host disease industry in the near future.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/184

Large unmet needs in the Gvhd management are one of the most important factors fueling growth of the graft versus host disease market. At present there are very few or no guidelines for management of graft versus host disease that can precisely maintain the data for the large population suffering from Gvhd, though certain recommendations for such therapies are in place.

Lack of regulatory guidelines pegs back growth of graft versus host disease market

The disease is orphan in nature, which can be one of the important factors affecting the lack of guidelines and treatment regimes. Lack of randomized clinical trials is another factor that contributes towards non-popularity of Gvhd due to the use of variable clinical trial endpoints conducted studies till date. This has resulted in inappropriate clinical evidences, which are not comparable and not directly applicable to all Gvhd patient groups. However, advancements in the process of early detection of symptoms is projected to support growth of the graft versus host disease market in the near future.

Major research universities in the GvHD market are engaged in research and development processes to further enhance the outcomes of the therapy. For instance, research conducted by the University Of Michigan, in 2017, revised the understanding regarding the graft vs. host disease origins, which can offer new direction for potential therapy in the near future.

Market players in the GvHD market focusing on inorganic growth strategies to strength product portfolio

The global graft versus host disease market is competitive and fragmented. Major players in the market are developing novel products and spending significantly in research and development, along with major acquisitions and collaborations to achieve competitive edge over their counterparts. For instance, Kalytera Therapeutics, Inc. acquired Talent Biotechs Ltd. – an Israeli-based developer of proprietary cannabidiol therapeutic. This is expected to favor the increase in company’s product portfolio. Some of the key players in the Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd.

Click To Reading More On Graft Versus Host Disease Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:sales@coherentmarketinsights.com